Heart failure & cardiomyopathiesCohort study

Hypotension in Heart Failure is Less Harmful if Associated with High or Increasing Doses of Heart Failure Medication: Insights from the Swedish Heart Failure Registry

Eur J Heart FailPublished

  • Registry-based cohort study
  • Swedish heart failure (HF) registry

Authors' conclusion

The association of lower SBP with higher risk of CVD/HFH is attenuated in patients with optimized HF medication.

Study context

Population
Patients with HF with reduced ejection fraction (HFrEF) in the Swedish HF registry (2000–2018)median age 74.0
Participants
42,040 patients
Exposure
Association of systolic BP (SBP) with outcomes by HF medication dose
Outcome
CV death and/or HF hospitalisation (cardiovascular death (CVD)/HF hospitalization (HFH))

Main finding

CVD/HFH per 10 mmHg higher baseline SBP

Adjusted hazard ratio

0.92

95% CI 0.92–0.93

per 10 mmHg higher SBP
adjusted HR 0.92 (95% CI 0.92–0.93)

Per 10 mmHg higher SBP, as printed

As reported in the abstract

Event-rate decrease per 10 mmHg SBP increase, untreated patients
10%
Event-rate decrease per 10 mmHg SBP increase, patients at maximum renin-angiotensin system (RAS) inhibitor and beta-blocker dose
7%

Observational data: associations, not effects.

Further findings

CV death/HF hospitalisation with decreasing SBP, by HF medication dose change

ComparisonHR (95% CI)
Decreasing SBP · stable dose1.10 (1.04–1.17)
Decreasing SBP · decreasing dose1.29 (1.18–1.42)
Decreasing SBP · increase in doses0.94 (0.86–1.02)
OutcomeValuesEstimate
SBP decrease >10 mmHg by HF medication dose change (patients with repeated measurements)Increased doses 9.9% · Stable/decreasing doses 24.6%
  • SBP decrease >10 mmHg by HF medication dose change (patients with repeated measurements): n = 13 761 with repeated measurements

Original publication

Hypotension in Heart Failure is Less Harmful if Associated with High or Increasing Doses of Heart Failure Medication: Insights from the Swedish Heart Failure Registry. Eur J Heart Fail. Published 21 November 2023. doi:10.1002/ejhf.3066

Summarised from the published abstract; every number is checked against it